| NCT04461886 |
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I |
https://ClinicalTrials.gov/show/NCT04461886 |
Recruiting |
Nobelpharma |
2022-04-30 |
| NCT03406208 |
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing |
https://ClinicalTrials.gov/show/NCT03406208 |
Recruiting |
Massachusetts General Hospital |
2022-01-30 |
| NCT03820778 |
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 |
https://ClinicalTrials.gov/show/NCT03820778 |
Enrolling by invitation |
Children’s National Research Institute |
2022-07-12 |
| NCT03363217 |
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. |
https://ClinicalTrials.gov/show/NCT03363217 |
Recruiting |
St. Justine’s Hospital |
2026-06-01 |
| NCT03326388 |
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours |
https://ClinicalTrials.gov/show/NCT03326388 |
Recruiting |
Great Ormond Street Hospital for Children NHS Foundation Trust |
2020-08-31 |
| NCT03310996 |
Non-invasive Stimulation in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT03310996 |
Completed |
University of Manchester |
2018-06-30 |
| NCT03095248 |
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
https://ClinicalTrials.gov/show/NCT03095248 |
Recruiting |
Children’s Hospital Medical Center, Cincinnati |
2021-05-31 |
| NCT02964884 |
Interventions for Reading Disabilities in NF1 |
https://ClinicalTrials.gov/show/NCT02964884 |
Recruiting |
Vanderbilt University |
2020-11-30 |
| NCT02944032 |
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT02944032 |
Recruiting |
Children’s National Research Institute |
2020-09-30 |
| NCT02839720 |
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma |
https://ClinicalTrials.gov/show/NCT02839720 |
Recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT02831257 |
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas |
https://ClinicalTrials.gov/show/NCT02831257 |
Active, not recruiting |
Massachusetts General Hospital |
2020-03-31 |
| NCT02811718 |
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02811718 |
Completed |
Massachusetts General Hospital |
2018-06-30 |
| NCT02728388 |
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II |
https://ClinicalTrials.gov/show/NCT02728388 |
Recruiting |
Medical College of Wisconsin |
2022-08-31 |
| NCT02718131 |
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT02718131 |
Active, not recruiting |
University of Alabama at Birmingham |
2021-05-31 |
| NCT02407405 |
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT02407405 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-08-31 |
| NCT02390752 |
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) |
https://ClinicalTrials.gov/show/NCT02390752 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-12-01 |
| NCT02211768 |
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT02211768 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-02-15 |
| NCT02422732 |
Functional Imaging and Reading Deficit in Children With NF1 |
https://ClinicalTrials.gov/show/NCT02422732 |
Completed |
University Hospital, Toulouse |
2015-04-30 |
| NCT02397967 |
Reading Disability in Children With NF1 |
https://ClinicalTrials.gov/show/NCT02397967 |
Completed |
University Hospital, Toulouse |
2014-04-30 |
| NCT02387177 |
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02387177 |
Completed |
Massachusetts General Hospital |
2017-12-31 |
| NCT02332902 |
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T |
https://ClinicalTrials.gov/show/NCT02332902 |
Completed |
The University of Texas Health Science Center, Houston |
2016-03-31 |
| NCT02298270 |
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02298270 |
Completed |
Massachusetts General Hospital |
2015-07-31 |
| NCT02246231 |
Effect of Implant Position on Magnetic Resonance Image Distortion |
https://ClinicalTrials.gov/show/NCT02246231 |
Completed |
Manchester University NHS Foundation Trust |
2015-01-31 |
| NCT02129647 |
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT02129647 |
Active, not recruiting |
NYU Langone Health |
2019-02-24 |
| NCT02124772 |
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations |
https://ClinicalTrials.gov/show/NCT02124772 |
Active, not recruiting |
Novartis |
2020-12-31 |
| NCT02104323 |
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
https://ClinicalTrials.gov/show/NCT02104323 |
Completed |
Beijing Tiantan Hospital |
2016-04-30 |
| NCT02101736 |
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults |
https://ClinicalTrials.gov/show/NCT02101736 |
Recruiting |
University of Alabama at Birmingham |
2021-05-31 |
| NCT02096471 |
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 |
https://ClinicalTrials.gov/show/NCT02096471 |
Completed |
University of Alabama at Birmingham |
2017-08-09 |
| NCT01275586 |
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01275586 |
Completed |
Indiana University |
2016-07-31 |
| NCT03871257 |
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma |
https://ClinicalTrials.gov/show/NCT03871257 |
Recruiting |
National Cancer Institute (NCI) |
2027-05-01 |
| NCT01968590 |
Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT01968590 |
Recruiting |
University of Utah |
2022-10-31 |
| NCT01851135 |
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT01851135 |
Completed |
Nantes University Hospital |
2016-04-30 |
| NCT01767792 |
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT01767792 |
Active, not recruiting |
University of Alabama at Birmingham |
2019-04-30 |
| NCT01682811 |
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) |
https://ClinicalTrials.gov/show/NCT01682811 |
Completed |
Medical College of Wisconsin |
2016-10-31 |
| NCT01673009 |
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01673009 |
Completed |
Indiana University |
2011-12-31 |
| NCT01633008 |
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain |
https://ClinicalTrials.gov/show/NCT01633008 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-05-01 |
| NCT01490476 |
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients |
https://ClinicalTrials.gov/show/NCT01490476 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2016-04-30 |
| NCT01419639 |
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 |
https://ClinicalTrials.gov/show/NCT01419639 |
Completed |
NYU Langone Health |
2012-12-31 |
| NCT01412892 |
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01412892 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2013-10-31 |
| NCT01347307 |
Stereotactic Body Radiotherapy for Spine Tumors |
https://ClinicalTrials.gov/show/NCT01347307 |
Completed |
Mercy Research |
2017-09-30 |
| NCT01345136 |
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma |
https://ClinicalTrials.gov/show/NCT01345136 |
Active, not recruiting |
Jonsson Comprehensive Cancer Center |
2021-02-01 |
| NCT04283669 |
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT04283669 |
Active, not recruiting |
University of Alabama at Birmingham |
2025-08-18 |
| NCT04201457 |
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration |
https://ClinicalTrials.gov/show/NCT04201457 |
Recruiting |
Pediatric Brain Tumor Consortium |
2025-02-28 |
| NCT04085159 |
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis |
https://ClinicalTrials.gov/show/NCT04085159 |
Recruiting |
Shenzhen Geno-Immune Medical Institute |
2021-01-31 |
| NCT03962543 |
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT03962543 |
Recruiting |
SpringWorks Therapeutics, Inc. |
2022-07-31 |
| NCT03888248 |
Whole-body Vibration in Children With Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT03888248 |
Enrolling by invitation |
Manchester University NHS Foundation Trust |
2020-07-31 |
| NCT03873610 |
Resiliency Training in Adolescents With NF1 and NF2 |
https://ClinicalTrials.gov/show/NCT03873610 |
Recruiting |
Massachusetts General Hospital |
2022-04-01 |
| NCT03826940 |
From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 |
https://ClinicalTrials.gov/show/NCT03826940 |
Recruiting |
University of Coimbra |
2020-01-31 |
| NCT03741101 |
Treatment of NF1-related Plexiform Neurofibroma With Trametinib |
https://ClinicalTrials.gov/show/NCT03741101 |
Recruiting |
Region Skane |
2022-07-31 |
| NCT03688568 |
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors |
https://ClinicalTrials.gov/show/NCT03688568 |
Recruiting |
Indiana University |
2020-09-01 |
| NCT03672838 |
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2) |
https://ClinicalTrials.gov/show/NCT03672838 |
Recruiting |
NYU Langone Health |
2020-06-30 |
| NCT03649165 |
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants |
https://ClinicalTrials.gov/show/NCT03649165 |
Completed |
AstraZeneca |
2018-10-21 |
| NCT03531814 |
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials |
https://ClinicalTrials.gov/show/NCT03531814 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-09-30 |
| NCT01207687 |
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) |
https://ClinicalTrials.gov/show/NCT01207687 |
Completed |
National Cancer Institute (NCI) |
2013-02-28 |
| NCT01140360 |
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01140360 |
Completed |
Indiana University |
2016-08-31 |
| NCT01125046 |
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas |
https://ClinicalTrials.gov/show/NCT01125046 |
Active, not recruiting |
Northwestern University |
2019-07-31 |
| NCT01089101 |
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma |
https://ClinicalTrials.gov/show/NCT01089101 |
Recruiting |
National Cancer Institute (NCI) |
2022-12-31 |
| NCT01058330 |
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 |
https://ClinicalTrials.gov/show/NCT01058330 |
Completed |
Shriners Hospitals for Children |
2014-02-28 |
| NCT01031901 |
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) |
https://ClinicalTrials.gov/show/NCT01031901 |
Completed |
The University of Texas Health Science Center, Houston |
2011-02-28 |
| NCT00973739 |
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
https://ClinicalTrials.gov/show/NCT00973739 |
Completed |
NYU Langone Health |
2012-10-31 |
| NCT00901849 |
Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT00901849 |
Completed |
Children’s National Research Institute |
2010-07-31 |
| NCT00865644 |
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00865644 |
Completed |
Massachusetts General Hospital |
2010-04-30 |
| NCT00853580 |
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT00853580 |
Completed |
University of Alabama at Birmingham |
2014-05-31 |
| NCT01362803 |
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors |
https://ClinicalTrials.gov/show/NCT01362803 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2019-03-29 |
| NCT03231306 |
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT03231306 |
Recruiting |
University of Alabama at Birmingham |
2022-12-31 |
| NCT03090971 |
Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 |
https://ClinicalTrials.gov/show/NCT03090971 |
Completed |
Fundação Educacional Serra dos Órgãos |
2017-03-23 |
| NCT02471339 |
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain |
https://ClinicalTrials.gov/show/NCT02471339 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-04-30 |
| NCT00754780 |
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00754780 |
Completed |
Mayo Clinic |
2004-08-31 |
| NCT00727233 |
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00727233 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-06-16 |
| NCT00657202 |
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00657202 |
Completed |
Massachusetts General Hospital |
2009-10-31 |
| NCT00634270 |
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00634270 |
Completed |
University of Alabama at Birmingham |
2014-11-30 |
| NCT00624234 |
Neurobiology and Treatment of Reading Disability in NF-1 |
https://ClinicalTrials.gov/show/NCT00624234 |
Completed |
Vanderbilt University |
2013-03-31 |
| NCT00396019 |
Study of PEG-Intron for Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00396019 |
Completed |
University of Pittsburgh |
2014-04-30 |
| NCT00352599 |
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) |
https://ClinicalTrials.gov/show/NCT00352599 |
Completed |
University of California, Los Angeles |
2014-03-31 |
| NCT00304083 |
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors |
https://ClinicalTrials.gov/show/NCT00304083 |
Completed |
Sarcoma Alliance for Research through Collaboration |
2014-06-30 |
| NCT00253474 |
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma |
https://ClinicalTrials.gov/show/NCT00253474 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00169611 |
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate |
https://ClinicalTrials.gov/show/NCT00169611 |
Completed |
Hospices Civils de Lyon |
2011-01-31 |
| NCT00076102 |
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00076102 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-04-01 |
| NCT00053937 |
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00053937 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00030264 |
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00030264 |
Completed |
Children’s Hospital of Philadelphia |
2013-12-31 |
| NCT00030043 |
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors |
https://ClinicalTrials.gov/show/NCT00030043 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00589784 |
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma |
https://ClinicalTrials.gov/show/NCT00589784 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-10-31 |
| NCT00352495 |
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma |
https://ClinicalTrials.gov/show/NCT00352495 |
Completed |
Children’s Oncology Group |
2011-09-30 |
| NCT00021541 |
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00021541 |
Completed |
National Institutes of Health Clinical Center (CC) |
2009-02-19 |
| NCT00004437 |
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 |
https://ClinicalTrials.gov/show/NCT00004437 |
Completed |
FDA Office of Orphan Products Development |
NA |